Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Sexual Dysfunction, Physiological 1Recurrence 1Non Small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Eunuchism 1Erectile Dysfunction 1Diffuse Intrinsic Pontine Glioma 1Astrocytoma 1Advanced Non-Small Cell Lung Cancer 1ALK-positive Non-small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Temozolomide 16Irinotecan 13Cyclophosphamide 11dinutuximab 9naxitamab 7Vincristine 7Carboplatin 6sargramostim 5Melphalan 5Granulocyte-Macrophage Colony-Stimulating Factor 5Etoposide 5fludarabine 4Topotecan 4Thiotepa 4Eflornithine 4Doxorubicin 4Cisplatin 4etoposide phosphate 3Zoledronic Acid 3Specimen Handling 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3saponin QA-21V1 2lutetium Lu 177 dotatate 2aldesleukin 2Vorinostat 2Stem Cell Transplantation 2Radiation 2Platinum 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroblastoma × lorlatinib × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡